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Supplementary information 2.  
Concomitant medications which preclude inclusion in the VICI trial. 
• Potassium-sparing diuretics.  
• Potassium-supplements. 
• Inhibitors of CYP 3A4 (e.g.amiodarone, diltiazem, fluconazole, itraconazole, ketoconazole, 
ritonavir, nelfinavir, saquinavir clarithromycin, telithromycin, erythromycin, verapamil, 
spironolactone and nefazodone). Note. Patients taking furosemide are eligible. 
• Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen). 
• Combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin 
receptor blocker (ARB). 
• Lithium, cyclosporine or tacrolimus. 
